Mylan Says Unnamed Inventor Invalidates Merck Vytorin Patent
Mylan Pharmaceuticals urged a Federal Circuit panel on Tuesday to invalidate Merck Sharp & Dohme Corp. patents covering the cholesterol drug Vytorin, claiming the drugmaker deceived the U.S. Patent and Trademark...To view the full article, register now.
Already a subscriber? Click here to view full article